Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron.
Laurie MT, Liu J, Sunshine S, Peng J, Black D, Mitchell AM, Mann SA, Pilarowski G, Zorn KC, Rubio L, Bravo S, Marquez C, Sabatino JJ, Mittl K, Petersen M, Havlir D, DeRisi J. Laurie MT, et al. Among authors: mittl k. J Infect Dis. 2022 Jun 1;225(11):1909-1914. doi: 10.1093/infdis/jiab635. J Infect Dis. 2022. PMID: 34979030 Free PMC article.
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.
Sabatino JJ Jr, Mittl K, Rowles WM, McPolin K, Rajan JV, Laurie MT, Zamecnik CR, Dandekar R, Alvarenga BD, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Augusto DG, Alexander JR, DeRisi JL, Hollenbach JA, Wilson MR, Zamvil SS, Bove R. Sabatino JJ Jr, et al. Among authors: mittl k. JCI Insight. 2022 Feb 22;7(4):e156978. doi: 10.1172/jci.insight.156978. JCI Insight. 2022. PMID: 35030101 Free PMC article.
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Novak F, Nilsson AC, Nielsen C, Holm DK, Østergaard K, Bystrup A, Byg KE, Johansen IS, Mittl K, Rowles W, Mcpolin K, Spencer C, Sagan S, Gerungan C, Wilson MR, Zamvil SS, Bove R, Sabatino JJ, Sejbaek T. Novak F, et al. Among authors: mittl k. Mult Scler Relat Disord. 2021 Nov;56:103251. doi: 10.1016/j.msard.2021.103251. Epub 2021 Sep 9. Mult Scler Relat Disord. 2021. PMID: 34571415 Free PMC article.
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
Bajwa HM, Novak F, Nilsson AC, Nielsen C, Holm DK, Østergaard K, Witt AH, Byg KE, Johansen IS, Mittl K, Rowles W, Zamvil SS, Bove R, Sabatino JJ, Sejbaek T. Bajwa HM, et al. Among authors: mittl k. Mult Scler Relat Disord. 2022 Apr;60:103729. doi: 10.1016/j.msard.2022.103729. Epub 2022 Mar 6. Mult Scler Relat Disord. 2022. PMID: 35334278 Free PMC article.
Antigen specificity of clonally-enriched CD8+ T cells in multiple sclerosis.
Mittl K, Hayashi F, Dandekar R, Schubert RD, Gerdts J, Oshiro L, Loudermilk R, Greenfield A, Augusto DG, Ramesh A, Tran E, Koshal K, Kizer K, Dreux J, Cagalingan A, Schustek F, Flood L, Moore T, Kirkemo LL, Cooper T, Harms M, Gomez R; University of California, San Francisco MS-EPIC Team; Sibener L, Cree BAC, Hauser SL, Hollenbach JA, Gee M, Wilson MR, Zamvil SS, Sabatino JJ. Mittl K, et al. bioRxiv [Preprint]. 2024 Oct 17:2024.09.07.611010. doi: 10.1101/2024.09.07.611010. bioRxiv. 2024. PMID: 39282370 Free PMC article. Preprint.
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
Novak F, Bajwa HM, Coia JE, Nilsson AC, Nielsen C, Holm DK, Østergaard K, Hvidt MVM, Byg KE, Johansen IS, Mittl K, Rowles W, Zamvil SS, Bove R, Sabatino JJ Jr, Sejbaek T. Novak F, et al. Among authors: mittl k. J Neurol Neurosurg Psychiatry. 2023 Nov;94(11):934-937. doi: 10.1136/jnnp-2022-330757. Epub 2023 Apr 25. J Neurol Neurosurg Psychiatry. 2023. PMID: 37185261 Free PMC article. Clinical Trial.
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ Jr, Mittl K, Rowles W, Zamecnik CR, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Alexander J, Mcpolin K, Chen P, Deshpande C, Wyse K, Maiese EM, Wilson MR, Zamvil SS, Bove R. Sabatino JJ Jr, et al. Among authors: mittl k. Mult Scler Relat Disord. 2023 Feb;70:104484. doi: 10.1016/j.msard.2022.104484. Epub 2022 Dec 28. Mult Scler Relat Disord. 2023. PMID: 36608538 Free PMC article.
SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron.
Laurie MT, Liu J, Sunshine S, Peng J, Black D, Mitchell AM, Mann SA, Pilarowski G, Zorn KC, Rubio L, Bravo S, Marquez C, Sabatino JJ Jr, Mittl K, Petersen M, Havlir D, DeRisi J. Laurie MT, et al. Among authors: mittl k. medRxiv [Preprint]. 2021 Dec 22:2021.09.08.21263095. doi: 10.1101/2021.09.08.21263095. medRxiv. 2021. Update in: J Infect Dis. 2022 Jun 1;225(11):1909-1914. doi: 10.1093/infdis/jiab635 PMID: 34981075 Free PMC article. Updated. Preprint.
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.
Sabatino JJ Jr, Mittl K, Rowles W, Mcpolin K, Rajan JV, Zamecnik CR, Dandekar R, Alvarenga BD, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Augusto DG, Alexander J, Hollenbach JA, Wilson MR, Zamvil SS, Bove R. Sabatino JJ Jr, et al. Among authors: mittl k. medRxiv [Preprint]. 2021 Sep 20:2021.09.10.21262933. doi: 10.1101/2021.09.10.21262933. medRxiv. 2021. Update in: JCI Insight. 2022 Feb 22;7(4):e156978. doi: 10.1172/jci.insight.156978 PMID: 34580672 Free PMC article. Updated. Preprint.